Media

WILSON THERAPEUTICS ANNOUNCES INITIAL PUBLIC OFFERING ON NASDAQ STOCKHOLM

Interim Report January-March 2016

Nexstim Plc announces the change of CEO

SAVE THE DATE – NORDIC NANOVECTOR CAPITAL MARKETS DAY

Onxeo Final Data from Mechanistic Livatag® Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment

Cerenis Therapeutics announces the publication of an initiation of coverage report by PORTZAMPARC, within the framework of the share’s market coverage

Nordic Nanovector ASA: Betalutin® continues to show promising efficacy and increasing Duration of Response (DoR)

WILSON THERAPEUTICS PRESENTS DATA ON DECUPRATE™ (WTX101) FROM ONGOING PHASE 2 STUDY AT THE INTERNATIONAL LIVER CONGRESS™ 2016

NORDIC NANOVECTOR ENTERS COLLABORATION WITH PAUL SCHERRER INSTITUTE TO DEVELOP NEW ANTIBODY RADIONUCLIDE CONJUGATES FOR TREATING LEUKAEMIAS